Evidence map›Paper›PMID 38137325›Full record

ArticleBiomedicines2023

Dupilumab-Associated Blepharoconjunctivitis: Clinical and Morphological Aspects.

Federica Serino, Valeria Dattilo, Michela Cennamo, Anna Maria Roszkowska, Massimo Gola, Manfredi Magliulo, Elisabetta Magnaterra, Rita Mencucci

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Federica SerinoEye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, 50139 Florence, Italy.ORCID 0000-0002-6629-0712
Valeria DattiloEye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, 50139 Florence, Italy.
Michela CennamoEye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, 50139 Florence, Italy.
Anna Maria RoszkowskaDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98166 Messina, Italy.ORCID 0000-0002-8083-3437
Massimo GolaAllergological and Pediatric Dermatology Unit, Azienda USL Toscana Centro, 500122 Florence, Italy.
Manfredi MagliuloAllergological and Pediatric Dermatology Unit, Azienda USL Toscana Centro, 500122 Florence, Italy.ORCID 0000-0003-0154-3173
Elisabetta MagnaterraAllergological and Pediatric Dermatology Unit, Azienda USL Toscana Centro, 500122 Florence, Italy.ORCID 0000-0002-3263-4353
Rita MencucciEye Clinic, Neuromuscular and Sense Organs Department, Careggi University Hospital, 50139 Florence, Italy.ORCID 0000-0003-1856-6363
Azienda Ospedaliero-Universitaria Careggi · ITAzienda Usl Toscana Centro · ITUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the clinical and morphologic changes in the ocular surface microstructure of patients affected with moderate-to-severe Atopic Dermatitis (AD) before and during Dupilumab treatment.

methodsThis is a monocentric observational study on thirty-three patients affected with AD before and during Dupilumab treatment. All patients underwent a slit-lamp examination: complete clinical assessment, Break Up Time test (BUT), Schirmer test, and corneal staining grading (Oxford scale) were performed. Meibomian Glands Dysfunction (MGD) evaluation (Meibography), Non-invasive Keratograph Break Up Time test (NIKBUT), Tear Meniscus Height (TMH), and ocular Redness Score (RS) have been investigated using an OCULUS Keratograph. In vivo images of the conjunctiva, cornea, and meibomian glands have been acquired by confocal microscopy.

resultsSixty-six eyes were included in our study: twenty-two eyes of 11 naive patients with indication for treatment but not in therapy yet (Group 1) and forty-four eyes of 22 patients treated with Dupilumab for at least 4 months (subcutaneous administration of 300 mg every 2 weeks) (Group 2). Either patients treated with Dupilumab or naive patients with moderate-to-severe forms of AD had a tear film instability (TBUT and NIKBUT reduced), whereas the quantity of the tear film was overall normal (Schirmer test and TMH), without statistically significant differences between the two groups. When Meibography was performed with the Keratograph, the difference between Group 1 and Group 2 was statistically significant in terms of Meiboscore (

conclusionsIn recent years, the use of Dupilumab has been increasing, but mild-to-severe conjunctivitis is a common side effect. Our major results demonstrate a loss of meibomian glands at the Keratograph examination: we can assume a reduced meibum secretion and an evaporative dry eye with MGD. We suggest that the inflammation of the ocular surface may involve not only the cornea and the conjunctiva, but also the meibomian glands, and Dupilumab may play a role. However, the frequency of clear conjunctivitis is not as common as reported in the literature.

Indexed as

atopic dermatitiscorneaDupilumabmeibomian glands

Identifiers

PMID38137325
PMCPMC10740631
OpenAlexW4388848715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.